Latest News
Important Information regarding Di-gesic and Doloxene.
Australian News, Media Release
We wish to advise you that the Administrative Appeals Tribunal (AAT) has granted Aspen Australia’s application to stay the cancellation of products containing dextropropoxyphene (Di-Gesic and Doloxene) from the ARTG. This allows us the opportunity to have our appeal of the Therapeutic Goods Administration’s (TGA) decision to cancel the registrations heard by the AAT.
South China Morning Post Article
Australian News, New Zealand News, Media Release
In a span of 11 years, Aspen Pharmacare Australia has become one of Australia's leading pharmaceutical companies, developing a reputation for reliable, regulated and affordable medicines. Aspen-marketed brands account for one out of seven prescriptions written in the country.
Business Review Australia Article
Australian News, New Zealand News, Media Release
Aspen Pharmacare Australia Expanding Global Business - from recent acquisition to expansion plans in Asia, Aspen Pharmacare Australia is ready to increase sales and markets.
Aspen Pharmacare Australia announces a new partnership with Eli Lilly Australia for Zyprexa®
Australian News, Announcements
Aspen Pharmacare Australia Pty Ltd (Aspen) is pleased to announce a new partnership with Eli Lilly Australia (Lilly) for Zyprexa® (olanzapine), a market leading medication for schizophrenia and bipolar disorder
Aspen Acquires Sigma's Pharmaceutical Business For AU$900 Million
Australian News, New Zealand News, Media Release
Aspen, South Africa's leading pharmaceutical company, has announced that all conditions precedent have been met for it to acquire the pharmaceutical business of Australian-based Sigma Pharmaceuticals Limited.
Formal Agreement Reached for $900 Million Sale of Pharmaceuticals Division to Aspen Pharmacare
Australian News, Announcements
On 16 August 2010, Sigma announced that it had agreed in principle to sell its Pharmaceuticals Division to the Aspen Pharmacare Holdings Limited group of companies for A$900 million.
Aspen to distribute Merck products
Australian News, Announcements
Effective immediately, Aspen is taking over the sales, distribution and marketing of a portfolio of dermatology products from Merck, with estimated annual sales of $50 million.
Stephen Saad, CEO of Aspen Holdings, comments on Sigma purchase
Australian News, New Zealand News, Announcements
An interview of Stephen Saad, CEO of Aspen Holdings.
Aspen Announcement to JSE
Australian News, Announcements
Announcement regarding the acquisition of the pharmaceutical business of Sigma Pharmaceuticals Limited by Aspen.
Aspen make a bid for Sigma
Australian News, Media Release
Aspen shareholders are advised that Aspen has submitted an indicative non-binding proposal to acquire, either directly or through a wholly-owned subsidiary, Sigma Pharmaceuticals Limited.
